

**Glenn T. Werneburg, MD, PhD**

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH

**Daniel D. Rhoads, MD**

Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH; Infection Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

# Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidance

## ABSTRACT

The urine culture, the cornerstone for laboratory diagnosis of urinary tract infection (UTI), is associated with a high frequency of false-positive and false-negative results, and its diagnostic threshold is debated. Urine culture takes days to result, and antibiotics are often initiated while awaiting final culture readings. Further, asymptomatic bacteriuria—the presence of bacteria in urine in the absence of UTI symptoms—generally does not warrant treatment. The authors review current expert guidance on the use of urine culture, including approaches to ordering, processing, and reporting of urine cultures, with the goal of reducing unnecessary antibiotic use and misdiagnosis of UTI.

## KEY POINTS

Appropriate ordering of urine culture involves documentation of proper (eg, clean-catch) collection, and testing only patients with documented signs and symptoms of UTI.

Examples of inappropriate practice are the inclusion of culture in standard order sets (emergency department, hospital admission, preoperative, altered mental status, and falls assessment), and ordering a urine culture in response to a change in urine characteristics.

The consensus panel guidance reemphasizes generally accepted principles: ie, that even cultures with uropathogen growth greater than 100,000 colony-forming units (CFU)/mL do not require treatment in patients without symptoms, and that true UTI may be associated with uropathogen growth less than 100,000 CFU/mL.

URINARY TRACT INFECTIONS (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect. It has a high frequency of false-positive and false-negative results, and its diagnostic threshold is debated. Also, urine culture takes 2 to 3 days to result, and antibiotics are often initiated empirically while awaiting final culture readings. Further, asymptomatic bacteriuria—the presence of bacteria in urine in the absence of UTI symptoms—generally does not warrant treatment.

Current guidance based on an expert panel consensus by Claeys et al<sup>1</sup> recommends appropriate laboratory urine testing and interpretation of the results when the potential for UTI is being assessed. The guidance describes approaches to reduce unnecessary antibiotic use and the misdiagnosis of UTI and is organized according to the procedure for urine culture: ordering, processing, and reporting.

The authors of the guidance, an expert panel representing multiple areas of expertise, used a modified Delphi approach to determine best practices in diagnostic stewardship relating to urine culture. The central tenets of the guidance are avoiding testing and treatment of asymptomatic bacteriuria, and avoiding fluoroquinolones as first-line treatment for acute cystitis, principles corroborated by other major guidelines.<sup>2-4</sup>

Here, we outline the current guidance and discuss its impact on daily practice. Finally, we discuss specific patient groups and scenarios to which the guidance will not apply.

doi:10.3949/ccjm.89a.22008

**TABLE 1**  
**Ordering, processing, and reporting urine cultures: Key points of the expert guidance**

| Stage      | Appropriate practices   |
|------------|---|
| Ordering   | Require documentation of proper (eg, clean-catch) collection<br><br>Only test patients with documented signs and symptoms of urinary tract infection  |
| Processing | Use a reflex-culture protocol when possible, so urine without inflammatory markers (ie, white blood cells) is not cultured, as this helps prevent microbial characterization and inappropriate treatment of asymptomatic bacteriuria<br><br>Do not routinely work up any isolates when more than 2 types of bacteria are recovered by culture   |
| Reporting  | Optimize laboratory reporting: <ul style="list-style-type: none"> <li>• Include a disclaimer that high colony counts can be present in asymptomatic bacteriuria</li> <li>• “Nudge” prescribers not to treat asymptomatic bacteriuria or mixed growth</li> <li>• Clearly define identified isolates as uropathogen or probable skin contaminant</li> <li>• Use antibiotic cascade reporting, which does not report fluoroquinolones as first-line antibiotics</li> </ul> |

Based on information in reference 1.

**■ CLINICAL SETTING**

The guidance<sup>1</sup> relates to urine culture diagnostic stewardship in both outpatient and inpatient settings and specifically addresses the emergency department, inpatient, ambulatory, and long-term care practice settings.

**■ INTENDED AUDIENCE**

This review is intended for clinicians who diagnose and treat UTI, and for those who perform or report urine studies. These include general practitioners, emergency medicine physicians, infectious disease physicians, geriatricians, and laboratory medicine medical directors. This review is also intended for urologists, for whom the discussion of exceptions to the guidance in urological patient cohorts is particularly relevant.

**■ WHO WROTE THE GUIDELINES?**

The guidance includes 18 general statements written by an expert panel chosen from geographically diverse practice settings. The panel included 15 individuals with specialization in healthcare epidemiology and quality improvement, medical informatics and decision support, infectious diseases, clinical microbiology, antimicrobial stewardship, and urology, and with expertise in UTI management, diagnostic stewardship, clinical microbiology, and infection prevention. Thirteen of the 15 panelists were physicians, and 10 of those were infectious disease physicians. No clinical pathologists trained and board-certified in the

general practice of laboratory medicine were on the panel.

The guidance panel reviewed relevant literature on diagnostic stewardship from electronic databases to generate a final list of clinical questions to guide the development of survey questions for use in the modified Delphi process. A modified Delphi approach using the RAND/UCLA Appropriateness Method<sup>5</sup> was used to determine best practices in diagnostic stewardship relating to urine culture. Guidance panel experts ranked their recommendations on a Likert scale, and subsequently met to further discuss points of disagreement. A second round of review was performed, and the final body of guidance statements was generated.

**■ WHAT ARE THE MAIN RECOMMENDATIONS?**

Key points of the guidance are summarized in **Table 1**.<sup>1</sup> The main recommendations focus on optimizing urine culture diagnostic stewardship and antibiotic stewardship. The recommendations are broadly classified by ordering, processing, and reporting of urine cultures, along with associated appropriate and inappropriate practices.

**Ordering urine cultures**

**Appropriate practice** for ordering a urine culture includes documentation of signs or symptoms (**Table 2**)<sup>1</sup> of UTI in order to obtain a urine culture, to replace stand-alone urine culture orders with a “reflex-culture” protocol (ie, when urinalysis and urine culture are ordered together, the culture is per-

**TABLE 2**  
**Ordering urine cultures: Appropriate and inappropriate signs and symptoms to document**

| Urinary catheter status            | Appropriate sign or symptom  | Inappropriate sign                                     |
|------------------------------------|--|--|
| Patient without a urinary catheter | Dysuria, suprapubic pain, flank pain, costovertebral angle tenderness, septic shock    | Altered mental status, change in urine characteristics |
| Patient with a urinary catheter    | Dysuria, suprapubic pain, flank pain, costovertebral angle tenderness, or septic shock | Change in urine characteristics                        |

Based on information in reference 1.

formed only if urinalysis criteria are met) based on urinalysis results, and to automatically cancel repeat urine cultures within 5 days of a positive culture, if during the same hospital admission.

**Inappropriate practice** is the inclusion of culture in standard order sets (emergency department, hospital admission, preoperative, altered mental status, and falls assessment), or ordering urine cultures in response to a change of urine characteristics.

**Processing urine cultures**

**Appropriate practice** includes using an elevated white blood cell count on urine microscopy as a criterion for reflex culture when a urine culture is ordered by a clinician. Further, the collection method (eg, midstream clean catch, indwelling catheter, in-and-out straight catheterization) should be documented before processing cultures.

**Inappropriate practice** includes automatically obtaining reflex cultures based on urinalysis results in cases where a urine culture was not specifically requested.

**Reporting urine cultures**

**Appropriate practice** should include urine culture reports informing clinicians that counts greater than 100,000 colony-forming units (CFU)/mL may not represent true infection in the absence of symptoms, and reminding clinicians not to treat asymptomatic bacteriuria or mixed flora. Further, the culture report should differentiate between typical uropathogens and contaminants. Identification and susceptibility testing of isolates should not be routinely reported when more than 2 unique bacterial isolates are present in culture.

For example, our clinical laboratory provides the following comments along with results of cultures with growth of 3 or more organisms: *Mixed microbiota. No further workup. Mixed microbiota can be due to urine contamination with skin bacteria at time of collection or*

*presence of a long-term urinary catheter. If a new culture is needed, please consider re-education of the patient on proper midstream collection technique or straight catheterization for urine collection.*

An additional appropriate practice, termed *cascade reporting*, is that antibiotics recommended by the Infectious Diseases Society of America (IDSA) should be preferentially reported if an organism is susceptible, and fluoroquinolone susceptibilities should be withheld unless there is resistance to preferred oral antibiotics.

**Inappropriate practice** would include suggesting not to treat if less than 100,000 CFU/mL of bacteria is recovered in culture, and withholding culture information and waiting for the prescriber to contact the clinical microbiology lab to release the results.

**WHAT IS DIFFERENT FROM PREVIOUS GUIDELINES?**

The goal of the current guidance is different from the IDSA/American Society for Microbiology (ASM) guidelines<sup>6</sup> in that the focus is the best implementation of urine testing for the optimal treatment for UTI. It seeks to provide system-based guidance to influence diagnostic stewardship on a large scale.

The 2018 IDSA/ASM “Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases,”<sup>6</sup> which includes urine culture guidance, does not disagree with any of the guidance offered by Claeys et al,<sup>1</sup> but it does offer additional points. The IDSA/ASM guide states that urine should be placed in boric acid (“gray-top”) preservative tubes if transported at room temperature. Alternatively, urine can be refrigerated after collection and during transport, or urine can be inoculated within 30 minutes of collection if not refrigerated and not preserved with boric acid. The IDSA/ASM guide also states that a reflex-culture protocol based on pyuria should be a locally approved policy.

The guidance by Claeys et al does not address preanalytical considerations to prevent bacterial overgrowth during transport. Preanalytical practice effectiveness is systematically reviewed elsewhere.<sup>7</sup> Additionally, it is beyond the scope of the guidance to inform as to how to create and implement a reflex-culture approach at a local level.

### ■ WHAT IS THE EXPECTED CLINICAL IMPACT?

The clinical impact of the guidance can be stratified into 2 main categories: reduction in unnecessary antibiotic use, which is good antimicrobial stewardship practice, and cost avoidance through decreased urine culture testing and inappropriate therapy, which is good diagnostic stewardship practice.

#### Reduction in antibiotic overuse

Antibiotic exposure is a known strong risk factor for antibiotic-resistant UTI and other infections.<sup>8,9</sup> Antibiotic use is associated with increased resistance at the population level.<sup>10</sup> Antibiotic exposure is also associated with increased risk for *Clostridioides difficile* colitis and vulvovaginal candidiasis due to disruption of the healthy microbiome.<sup>11,12</sup> Thus, reducing the unnecessary use of antibiotics is a critical aspect of delaying and minimizing the emergence of resistance and reducing collateral pathology. The guidance by Claeys et al provides actionable measures to reduce unnecessary antibiotic use during each stage of the urine culture process, ie, ordering, processing, and reporting.

Recommended measures are provided to avoid unnecessary detection and treatment of asymptomatic bacteriuria. In one study, about 70% of patients with asymptomatic bacteriuria were treated with antibiotics,<sup>13</sup> despite the lack of benefit and the discordance with existing guidelines.<sup>2-4,14</sup> The current recommendation is that the clinician be prompted to document signs and symptoms of infection when requesting a urine culture. The assignment of a symptom complex to a culture is designed to reduce testing in the absence of UTI symptoms and, thus, to subsequently reduce unnecessary treatment of asymptomatic bacteriuria. Further guidance designed to limit treatment of asymptomatic bacteriuria includes the recommendation that culture reports remind, or “nudge,” clinicians to not treat asymptomatic bacteriuria, and that even high colony counts (> 100,000 CFU/mL) may not represent true infection in the absence of signs and symptoms.

Further, the guidance provides a strategy to decrease the time and resources required to achieve a final lab-

oratory result by screening with urinalysis before culture. A urine culture generally takes 2 or more days to return a result with antibiotic susceptibility test interpretations. However, if a reflex-culture protocol is employed as the guidance recommends, the time to final result would often be significantly reduced, and culture would be obviated. This practice could lead to a reduction in unnecessary antibiotic use.

#### Cost reduction

In 2019, there were more than 36 million hospitalizations in the United States.<sup>15</sup> It is estimated that about 27% of hospitalizations are associated with a urine culture.<sup>16</sup> At about \$10 per culture (based on the Medicare clinical laboratory fee schedule CPT code 87086),<sup>17</sup> this translates to almost \$100 million annually in the inpatient setting alone. These data, coupled with the large quantity of urine cultures obtained in the emergency, ambulatory, and long-term care settings, underscore the opportunity for cost avoidance associated with a reflex-culture protocol. Further cost savings would be associated with the reduction in treatment of asymptomatic bacteriuria.

### ■ DO OTHER SOCIETIES AGREE OR DISAGREE?

The main tenet of nontreatment of asymptomatic bacteriuria described in the guidance by Claeys et al<sup>1</sup> is agreed upon by other major societies. IDSA, the American Urological Association (AUA), and the European Association of Urology (EAU) agree that asymptomatic bacteriuria should generally not be treated outside the context of pregnancy or prior to a subset of urologic interventions.<sup>2,4,18</sup> The guidance is also corroborated by the American Board of Internal Medicine’s Choosing Wisely health-education campaign, which recommends not obtaining urine cultures in the absence of symptoms and not treating asymptomatic bacteriuria.<sup>19,20</sup> The IDSA/ASM guide to laboratory testing recommends that a reflex-culture policy be established locally.<sup>6</sup>

Existing guidelines vary as to the cutoff for uropathogen growth on standard culture. For example, the US Centers for Disease Control and Prevention requires at least 100,000 CFU/mL on urine culture to meet its criteria for diagnosis of UTI.<sup>21</sup> Conversely, the IDSA/ASM guidelines have a more flexible threshold and include growth less than 100,000 CFU/mL.<sup>6</sup>

#### Fluoroquinolones

Similar to the guidance by Claeys et al,<sup>1</sup> the guidelines from the IDSA, AUA, and EAU emphasize that fluoroquinolones should be avoided in uncomplicated



cystitis. For example, the IDSA/European Society for Microbiology and Infectious Diseases guidelines<sup>3</sup> note that fluoroquinolones are highly efficacious but have the propensity for significant off-target effects and should be reserved for uses other than acute cystitis, and should be considered an alternative rather than a first-line regimen. The EAU guidelines state that fluoroquinolones should not be used to treat uncomplicated cystitis,<sup>4</sup> and the AUA guidelines<sup>2</sup> note that the serious adverse effects associated with fluoroquinolones including tendonitis, tendon rupture, QT interval prolongation, and *C difficile* infection generally outweigh the benefits in uncomplicated UTI. Of note, the IDSA, AUA, and EAU recommendations do not necessarily apply to patients with complicated UTI (eg, aberrant anatomy, foreign body) or compromised immunity.

■ **HOW WILL THIS CHANGE DAILY PRACTICE?**

Most of the statements in the Claeys et al guidance are generally accepted good practice. However, the guidance also adds weight to the increasingly common practice of using a reflex-culture approach to prevent the culture of urine specimens in which no inflammation is present (ie, no white blood cells).

The guidance deemphasizes the traditional cutoff of 100,000 CFU/mL as a diagnostic criterion for UTI, which is consistent with IDSA's previous deemphasis of this cutoff.<sup>6</sup> The cutoff of 100,000 CFU/mL was developed based on a population with pyelonephritis and has since proven to be inadequate.<sup>22-27</sup> The current guidance reemphasizes generally accepted principles, ie, that even cultures with uropathogen growth of greater than 100,000 CFU/mL do not require treatment in patients without symptoms, and that true UTI may be associated with uropathogen growth of less than 100,000 CFU/mL.<sup>1</sup>

The framework provided for the stewardship of fluoroquinolone use may reduce prescription of this drug class. In 2016, the US Food and Drug Administration added a boxed warning to fluoroquinolones due to their association with tendonitis and tendon rupture.<sup>28</sup> However, there is evidence that the boxed warning has had little effect on prescription patterns of fluoroquinolones for uncomplicated UTI,<sup>29,30</sup> and little effect on the high rates of fluoroquinolone resistance.<sup>31</sup> We believe that one of the greatest impacts of the current guidance could be in reversing these trends in daily practice by encouraging laboratories to avoid reporting fluoroquinolones as routine, first-line antibiotics for UTI.

■ **SPECIAL CONSIDERATIONS:  
WHEN WOULD THE GUIDANCE NOT APPLY?**

The guidance by Claeys et al does not apply to a number of clinical scenarios. Children, pregnant patients, renal transplant recipients, and severely immunocompromised patients were specifically excluded. However, screening for and treatment of asymptomatic bacteriuria is indicated in pregnancy,<sup>18</sup> and the benefits of treatment may outweigh the risks.<sup>32</sup>

**Considerations for patients with urologic conditions**

Screening for and treating asymptomatic bacteriuria is indicated prior to urologic surgical procedures that involve manipulation of the upper urinary tract or that cause mucosal trauma,<sup>18</sup> and the benefits of treatment may outweigh the risks.<sup>33</sup>

For patients who have a urinary catheter or who require intermittent catheterization, and for patients with neurogenic lower urinary tract dysfunction or bowel interposition in the urinary tract (eg, ileal conduit, neobladder), the utility of a reflex-culture approach has not been empirically established. Further, the IDSA guidance for catheter-associated UTI states that pyuria should not be used to differentiate between catheter-associated UTI and asymptomatic bacteriuria.<sup>34</sup> UTI symptoms in these patients may be subtle and variable and can include increased spasticity, autonomic dysreflexia, and a sense of unease.<sup>34-36</sup> Symptoms must be considered in the context of the physical examination and urine studies, especially given that the urine of these patients is generally chronically colonized with bacteria.

**Other patients under urologic care**

Urine cultures with complete antimicrobial susceptibility profiles may be required in urologic patients regardless of urinalysis results. Such circumstances may include contexts prior to or following urologic procedures, as well as cases of suspected prostatitis, epididymo-orchitis, fistulae, or recurrent UTI.

The clinical appropriateness of performing cultures for urology patients should be at the discretion of the supervising urologist or urology practitioner, and stand-alone cultures should not be reverted to reflex culture in urologic patients without prior discussion with the urology team. Similarly, a culture within 5 days of another culture should not be cancelled in a urologic patient before a discussion with the team requesting the culture. Such a culture may be necessary in the context of refractory symptoms, to assess the possibility of recurrent infection or continued contamination. In urologic patients, species-level

identification and antimicrobial susceptibility testing of all isolates grown in urine may be necessary before endourologic procedures, even in cases of more than 2 organisms, as polymicrobial interactions can play a role in urologic infection,<sup>37</sup> and so this should be left to the discretion of the urology team.

In select cases of UTI, fluoroquinolone use is appropriate. For example, the EAU guidance states that fluoroquinolones are an effective oral regimen for uncomplicated pyelonephritis.<sup>4</sup> Further, fluoroquinolones often exhibit excellent penetration of the prostate and thus are associated with significant benefit, particularly if there is suspicion for prostatitis, or in patients with febrile or recurrent UTI with prostatic involvement.<sup>4,38</sup> Thus, fluoroquinolone susceptibilities must be reported in such cases

## Other considerations

In daily practice, a balance must be achieved between diagnostic stewardship and clinical practicality. For example, the guidance places additional ordering demands on the clinician, and there should be a method in place to rapidly designate an exception to the laboratory that processes the specimens. A series of “hard stops” for the clinician when placing orders may lead to inappropriate care when such hard stops are not applicable, as in the exceptional circumstances discussed above.

In early urosepsis, a subset of patients may not be

able to describe symptoms, but changes in behavior or mental status may be witnessed or reported. Even in the absence of a catheter, the completion of a urine culture with antimicrobial susceptibility testing should be based on clinical discretion.

In some patients with catheters, UTI may present with fever without septic shock,<sup>34</sup> particularly in those unable to communicate, and thus urine culture should be processed at the discretion of the requesting clinician.

Recently, machine learning has been shown to improve antimicrobial stewardship. Specifically, the use of machine learning-generated antibiotic recommendations was associated with minimization of antimicrobial resistance.<sup>39</sup> As these models mature and undergo further validation, their integration within antimicrobial and diagnostic stewardship is poised to lead to further reduction in antibiotic overuse, antimicrobial resistance, and financial burden to patients and the healthcare systems. ■

## DISCLOSURES

Dr. Rhoads reports work as advisor or review panel participant with BD Diagnostics, Luminox, Roche Diagnostics, Talis Biomedical, and Thermo Fisher Scientific; teaching and speaking with Cepheid; and research (principal investigator) with bioMerieux, Cepheid, Cleveland Diagnostics, Hologic, Luminox, Q-Linea, Qiagen, Specific Diagnostics, Thermo Fisher Scientific, and Vela Diagnostics. Dr. Werneburg reports no relevant financial relationships which, in the context of his contributions, could be perceived as a potential conflict of interest.

## REFERENCES

1. **Claeys KC, Trautner BW, Leekha S, et al.** Optimal urine culture diagnostic stewardship practice—results from an expert modified-Delphi procedure. *Clin Infect Dis* 2021; 75(3):382–389. doi:10.1093/cid/ciab987
2. **Anger J, Lee U, Ackerman AL, et al.** Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. *J Urol* 2019; 202(2):282–289. doi:10.1097/JU.000000000000296
3. **Gupta K, Hooton TM, Naber KG, et al.** International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* 2011; 52(5):e103–e120. doi:10.1093/cid/ciq257
4. **Bonkat G, Bartoletti R, Bruyère F, et al.** EAU Guidelines on Urological Infections. Available at: <https://uroweb.org/guidelines/urological-infections>. Accessed September 6, 2022.
5. **Fitch K, Bernstein SJ, Aguilar MD, et al.** The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, CA: RAND Corporation; 2001.
6. **Miller JM, Binnicker MJ, Campbell S, et al.** A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. *Clin Infect Dis* 2018; 67(6):e1–e94. doi:10.1093/cid/ciy381
7. **LaRocco MT, Franek J, Leibach EK, et al.** Effectiveness of preanalytic practices on contamination and diagnostic accuracy of urine cultures: a laboratory medicine best practices systematic review and meta-analysis. *Clin Microbiol Rev* 2016; 29(1):105–147. doi:10.1128/CMR.00030-15
8. **Hillier S, Roberts Z, Dunstan F, Butler C, Howard A, Palmer S.** Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study. *J Antimicrob Chemother* 2007; 60(1):92–99. doi:10.1093/jac/dkm141
9. **Ventola CL.** The antibiotic resistance crisis: part 1: causes and threats. *P T* 2015; 40(4):277–283. PMID:25859123
10. **Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group.** Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *Lancet* 2005; 365(9459):579–587. doi:10.1016/S0140-6736(05)17907-0
11. **Bignardi GE.** Risk factors for Clostridium difficile infection. *J Hosp Infect* 1998; 40(1):1–15. doi:10.1016/S0195-6701(98)90019-6
12. **Shukla A, Sobel JD.** Vulvovaginitis caused by candida species following antibiotic exposure. *Curr Infect Dis Rep* 2019; 21(11):44. doi:10.1007/s11908-019-0700-y
13. **Petty LA, Vaughn VM, Flanders SA, et al.** Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients. *JAMA Intern Med* 2019; 179(11):1519–1527. doi:10.1001/jamainternmed.2019.2871
14. **Petty LA, Vaughn VM, Flanders SA, et al.** Risk factors and outcomes associated with treatment of asymptomatic bacteriuria in hospitalized patients. *JAMA Intern Med* 2019; 179(11):1519–1527. doi:10.1001/jamainternmed.2019.2871
15. **American Hospital Association.** Fast facts on US hospitals, 2021. Updated January 2021. Available at: <https://www.aha.org/system/files/media/file/2021/01/Fast-Facts-2021-table-FY19-data-14jan21.pdf>. Accessed September 8, 2022.
16. **Horstman MJ, Spiegelman A, Naik AD, Trautner BW.** National patterns of urine testing during inpatient admission. *Clin Infect Dis* 2017; 65(7):1199–1205. doi:10.1093/cid/cix424

17. **Medicare Guidelines.** CPT CODE 87086, 87186, 87184, 87088. Available at: <https://medicarepaymentandreimbursement.com/2016/09/cpt-code-87086-87186-87184-medicare.html>. Accessed September 8, 2022.
18. **Nicolle LE, Gupta K, Bradley SF, et al.** Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases* 2019; 68(10):e83–e110. PMID:30895288
19. **Infectious Diseases Society of America.** Don't treat asymptomatic bacteriuria with antibiotics. February 23, 2015. Available at: <https://www.choosingwisely.org/clinician-lists/infectious-diseases-society-antibiotics-for-bacteriuria/>. Accessed September 19, 2022.
20. **Choosing Wisely.** American Society for Microbiology. Do not order urine cultures unless patients have symptoms consistent with urinary tract infection (UTI). August 5, 2020. Available at: <https://www.choosingwisely.org/clinician-lists/asm-do-not-order-urine-cultures-unless-patients-have-symptoms-consistent-with-urinary-tract-infection-uti/>. Accessed September 8, 2022.
21. **Centers for Disease Control and Prevention.** National Healthcare Safety Network. Urinary tract infection (catheter-associated urinary tract infection [CAUTI] and non-catheter-associated urinary tract infection [UTI]) events. Device-associated Module UTI. January 2022. Available at: <https://www.cdc.gov/nhsn/pdfs/pscmanual/7psccauti-current.pdf>. Accessed September 8, 2022.
22. **Kass EH.** Chemotherapeutic and antibiotic drugs in the management of infections of the urinary tract. *Am J Med* 1955; 18(5): 764–781. doi:10.1016/0002-9343(55)90190-x
23. **Kass EH.** Bacteriuria and the diagnosis of infections of the urinary tract; with observations on the use of methionine as a urinary anti-septic. *AMA Arch Intern Med* 1957; 100(5):709–714. doi:10.1001/archinte.1957.00260110025004
24. **Kass EH.** Asymptomatic infections of the urinary tract. 1956. *J Urol* 2002; 167(2 Pt 2):1016–1021. doi:10.1016/s0022-5347(02)80328-7
25. **Semeniuk H, Church D.** Evaluation of the leukocyte esterase and nitrite urine dipstick screening tests for detection of bacteriuria in women with suspected uncomplicated urinary tract infections. *J Clin Microbiol* 1999; 37(9):3051–3052. doi:10.1128/JCM.37.9.3051-3052.1999
26. **Kunin CM, White LV, Hua TH.** A reassessment of the importance of 'low-count' bacteriuria in young women with acute urinary symptoms. *Ann Intern Med* 1993; 119(6):454–460. doi:10.7326/0003-4819-119-6-199309150-00002
27. **Stamm WE, Running K, McKevitt M, Counts GW, Turck M, Holmes KK.** Treatment of the acute urethral syndrome. *N Engl J Med* 1981; 304(16):956–958. doi:10.1056/NEJM198104163041608
28. **Tanne JH.** FDA adds "black box" warning label to fluoroquinolone antibiotics. *BMJ* 2008; 337(7662):a816. doi:10.1136/bmj.a816
29. **Cowart K, Worley M, Rouby NE, Sando K.** Evaluation of FDA boxed warning on prescribing patterns of fluoroquinolones for uncomplicated urinary tract infections. *Ann Pharmacother* 2019; 53(12): 1192–1199. doi:10.1177/1060028019865224
30. **Bratsman A, Mathias K, Laubscher R, Grigoryan L, Rose S.** Outpatient fluoroquinolone prescribing patterns before and after US FDA boxed warning. *Pharmacoepidemiol Drug Saf* 2020; 29(6):701–707. doi:10.1002/pds.5018
31. **Johnson L, Sabel A, Burman WJ, et al.** Emergence of fluoroquinolone resistance in outpatient urinary *Escherichia coli* isolates. *Am J Med* 2008; 121(10):876–884. doi:10.1016/j.amjmed.2008.04.039
32. **Small FM, Vazquez JC.** Antibiotics for asymptomatic bacteriuria in pregnancy. *Cochrane Database Syst Rev* 2019; 2019(11):CD000490. doi:10.1002/14651858.CD000490.pub4
33. **Köves B, Cai T, Veeratterapillay R, et al.** Benefits and harms of treatment of asymptomatic bacteriuria: a systematic review and meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. *Eur Urol* 2017; 72(6):865–868. doi:10.1016/j.eururo.2017.07.014
34. **Hooton TM, Bradley SF, Cardenas DD, et al.** Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis* 2010; 50(5): 625–663. doi:10.1086/650482
35. **Skelton-Dudley F, Doan J, Suda K, Holmes SA, Evans C, Trautner B.** Spinal cord injury creates unique challenges in diagnosis and management of catheter-associated urinary tract infection. *Top Spinal Cord Inj Rehabil* 2019; 25(4):331–339. doi:10.1310/sci2504-331
36. **Werneburg GT.** Catheter-associated urinary tract infections: current challenges and future prospects. *Res Rep Urol* 2022; 14:109–133. doi:10.2147/RRU.S273663
37. **Gaston JR, Johnson AO, Bair KL, White AN, Armbruster CE.** Polymicrobial interactions in the urinary tract: is the enemy of my enemy my friend? *Infect Immun* 2021; IAI.00652-20. doi:10.1128/IAI.00652-20
38. **Brede CM, Shoskes DA.** The etiology and management of acute prostatitis. *Nat Rev Urol* 2011; 8(4):207–212. doi:10.1038/nrurol.2011.22
39. **Stracy M, Snitser O, Yelin I, et al.** Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections. *Science* 2022; 375(6583):889–894. doi:10.1126/science.abg9868

.....  
**Address:** Glenn T. Werneburg, MD, PhD, Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [wernebg@ccf.org](mailto:wernebg@ccf.org)